CMPI
Income statement / Annual
Last year (2021), Checkmate Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2021, Checkmate Pharmaceuticals, Inc.'s net income was -$61.41 M.
See Checkmate Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$45.82 M
|
$26.72 M
|
$24.25 M
|
$18.17 M
|
| General & Administrative Expenses |
$15.65 M
|
$10.19 M
|
$4.64 M
|
$2.82 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$15.65 M
|
$10.19 M
|
$4.64 M
|
$2.82 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$61.47 M
|
$36.90 M
|
$28.89 M
|
$20.99 M
|
| Cost And Expenses |
$61.47 M
|
$36.90 M
|
$28.89 M
|
$20.99 M
|
| Interest Income |
$100.00 K
|
$79.00 K
|
$197.00 K
|
$180.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$66.00 K
|
$188.00 K
|
$597.00 K
|
$180.00 K
|
| EBITDA |
-$61.34 M |
-$36.72 M |
-$28.29 M |
-$20.81 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$0.00
|
-$4.00 K
|
$597.00 K
|
$180.00 K
|
| Income Before Tax |
-$61.41 M
|
-$36.91 M
|
-$28.29 M
|
-$20.81 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$61.41 M
|
-$36.91 M
|
-$28.29 M
|
-$20.81 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
| EPS |
-2.84 |
-3.86 |
-3.44 |
-2.53 |
| EPS Diluted |
-2.84 |
-3.86 |
-3.44 |
-2.53 |
| Weighted Average Shares Out |
$21.63 M
|
$9.56 M
|
$8.22 M
|
$8.22 M
|
| Weighted Average Shares Out Diluted |
$21.63 M
|
$9.56 M
|
$8.22 M
|
$8.22 M
|
| Link |
|
|
|
|
